| 1 |
31833955 | Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. | 2020 Mar |
1 |
| 2 |
31957165 | Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours. | 2020 Feb |
3 |
| 3 |
32024476 | Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. | 2020 Feb 5 |
1 |
| 4 |
31673329 | Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. | 2019 |
1 |
| 5 |
31689840 | Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report. | 2019 Nov |
2 |
| 6 |
31708372 | Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects. | 2019 Dec |
3 |